Edison Investment Research - Blue Cap (B7E) Sticking at it

Report

Edison Investment Research

Richard Finch

Sticking at it

Blue Cap is set to benefit from recent potentially transformative deals. The projected turnaround of Neschen may yield a step-change in profit, while the disposal of Biolink on a chemical industry-leading multiple confirms the success of management’s exit strategy. Otherwise, a strong, coherent business model is evident in a solid financial record and outlook. Indeed, current consensus forecasts appear not to reflect adequately the general improvement in trading and this virtual de-gearing; adjusted 2017e EV/EBITDA of under 7x ignores the proven corporate success and increasingly ambitious investment.

17/07/2017 10 EN

Underlying

Blue Cap

Blue Cap AG is a Germany-based holding company investing in medium-sized companies in the industry sector. The Company's portfolio includes companies in the areas of adhesives, special machinery, medical and measurement technology and precious metals. It distinguishes five business segments: Coating technology, Adhesive technology, Production technology, Medical technology, Precious metal recycling and trade. Its portfolio companies include NESCHEN Coating GmbH, a producer of adhesive-coated films; PLANATOL GmbH, a producer of glues; Gaemmerler GmbH, a manufacturer of printing systems; nokra Optische Prueftechnik und Automation GmbH, a provider of measuring and testing systems; em-tec GmbH, a developer of blood flow measuring devices; INHECO Industrial Heating and Cooling GmbH, a developer of thermo-electric components; Carl Schaefer Gold- und Silberscheideanstalt GmbH, a precious metals processing company, and knauer Holding GmbH & Co KG, a plastic cup supplier, among others.

See profile

DE000A0JM2M1 Germany

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Richard Finch

Other Reports on these Companies

EQS Group AG

EQS-News: Blue Cap AG publishes 2023 annual report and proposes dividend of EUR 0.65 per share

EQS-News: Blue Cap AG / Key word(s): Annual Report/Dividend Blue Cap AG publishes 2023 annual report and proposes dividend of EUR 0.65 per share 24.04.2024 / 07:09 CET/CEST The issuer is solely responsible for the content of this announcement. Group revenue in financial year 2023 at EUR 273.3 million, adjusted EBITDA margin of 8.5% Net asset value (NAV) amounts to EUR 112.3 million as at 31 December 2023 Dividend proposal of EUR 0.65 per share follows proven dividend policy For 2024, the Executive Board forecasts revenue of EUR 270-290 million and an adjusted EBITDA ma...

April 24, 2024 April 24, 2024 1 EN

EQS Group AG

EQS-News: Blue Cap AG veröffentlicht Geschäftsbericht 2023 und schlägt Dividende von 0,65 Euro je Aktie vor

EQS-News: Blue Cap AG / Schlagwort(e): Jahresbericht/Dividende Blue Cap AG veröffentlicht Geschäftsbericht 2023 und schlägt Dividende von 0,65 Euro je Aktie vor 24.04.2024 / 07:09 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Konzernumsatz im Geschäftsjahr 2023 bei 273,3 Mio. Euro, adjusted EBITDA-Marge von 8,5 % Net Asset Value (NAV) per 31.12.2023 beläuft sich auf 112,3 Mio. Euro Dividendenvorschlag von 0,65 Euro je Aktie folgt bewährter Dividendenpolitik Für 2024 prognostiziert der Vorstand einen Umsatz von 270-290 Mio. Euro ...

April 24, 2024 April 24, 2024 1 DE

SmartInsider

Blue Cap AG: 1 director

A director at Blue Cap AG bought 2,000 shares at 17.865EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

Free Trial

March 14, 2024 March 14, 2024 1 EN

Custodian Property Income REIT - Significant uplift in fully covered DPS

Custodian Property Income REIT (CREI) produced a strong Q424 performance, driven by leasing progress and rental growth, rounding off a positive year. Reflecting FY24 performance, the company will pay a special dividend of 0.3p per share, additional to aggregate quarterly DPS of 5.5p, fully covered by EPRA earnings. The FY25 annual DPS target is increased by 9% to 6.0p, underpinned by the continuing strength of the commercial property occupier market and CREI’s increasing confidence in the outlook.

13h / 14m 13h / 14m 1 EN

Pedro Fonseca

Pedro Fonseca

Canadian General Investments - Adding to positive long-term performance record

Canadian General Investments (CGI) has delivered a very commendable long-term performance versus the Canadian market. Longstanding manager Greg Eckel at Morgan Meighen & Associates (MMA) is unphased by stock market volatility, following a fundamental, long-term approach to stock selection. He has taken advantage of the maximum 25% permitted allocation to US stocks to increase CGI’s returns, including a position in NVIDIA, which has been in the portfolio since 2016. The manager is unconstrained by index sector weightings and has had an underweight exposure to financial stocks for many years. Ho...

17h 17h 1 EN

Sean Conroy

Sean Conroy

Recce Pharmaceuticals - Advances on several fronts

Recce Pharmaceuticals has reported several encouraging developments in recent weeks for its lead development compound RECCE® 327 (R327). The intravenous (IV) R327 formulation is advancing to a higher dose level (4,000mg) in its ongoing Phase I/II rapid infusion study and the company is progressing in its plan to submit a US Investigational New Drug (IND) application to commence a US Phase II complicated urinary tract infection (cUTI) study before end-CY24. Recce is also planning to start an Indonesian Phase III registrational study in Q3 CY24, which we anticipate could lead to initial commerci...

18h / 50m 18h / 50m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN